An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ
Open Access
- 23 January 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 9 (1), R8
- https://doi.org/10.1186/bcr1641
Abstract
Introduction Heparan sulphate proteoglycan syndecan-1 modulates cell proliferation, adhesion, migration and angiogenesis. It is a coreceptor for the hepatocyte growth factor receptor c-met, and its coexpression with E-cadherin is synchronously regulated during epithelial-mesenchymal transition. In breast cancer, changes in the expression of syndecan-1, E-cadherin and c-met correlate with poor prognosis. In this study we evaluated whether coexpression of these functionally linked prognostic markers constitutes an expression signature in ductal carcinoma in situ (DCIS) of the breast that may promote cell proliferation and (lymph)angiogenesis. Methods Expression of syndecan-1, E-cadherin and c-met was detected immunohistochemically using a tissue microarray in tumour specimens from 200 DCIS patients. Results were correlated with the expression patterns of angiogenic and lymphangiogenic markers. Coexpression of the three prognostic markers was evaluated in human breast cancer cells by confocal immunofluorescence microscopy and RT-PCR. Results Coexpression and membrane colocalization of the three markers was confirmed in MCF-7 cells. E-cadherin expression decreased, and c-met expression increased progressively in more aggressive cell lines. Tissue microarray analysis revealed strong positive staining of tumour cells for syndecan-1 in 72%, E-cadherin in 67.8% and c-met in 48.6% of DCIS. E-cadherin expression was significantly associated with c-met and syndecan-1. Expression of c-met and syndecan-1 was significantly more frequent in the subgroup of patients with pure DCIS than in those with DCIS and a coexisting invasive carcinoma. Levels of c-met and syndecan-1 expression were associated with HER2 expression. Expression of c-met significantly correlated with expression of endothelin A and B receptors, vascular endothelial growth factor (VEGF)-A and fibroblast growth factor receptor-1, whereas E-cadherin expression correlated significantly with endothelin A receptor, VEGF-A and VEGF-C staining. Conclusion Syndecan-1, E-cadherin and c-met constitute a marker signature associated with angiogenic and lymphangiogenic factors in DCIS. This coexpression may reflect a state of parallel activation of different signal transduction pathways, promoting tumour cell proliferation and angiogenesis. Our findings have implications for future therapeutic approaches in terms of a multiple target approach, which may be useful early in breast cancer progression.Keywords
This publication has 76 references indexed in Scilit:
- The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinomaInternational Journal of Cancer, 2006
- Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancerBritish Journal of Cancer, 2006
- Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtypeBreast Cancer Research and Treatment, 2006
- Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer CellsCancer Research, 2005
- E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significanceHistopathology, 2005
- The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cellsThe Journal of cell biology, 2004
- Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysisZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Differential Expression of E-Cadherin in Lobular and Ductal Neoplasms of the Breast and Its Biologic and Diagnostic ImplicationsAmerican Journal of Clinical Pathology, 2001
- Altered expression of E-cadherin in breast cancerEuropean Journal Of Cancer, 2000
- c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinomaHistopathology, 2000